Is Keytruda + Chemotherapy Effective for Breast Cancer?
Is Keytruda + Chemotherapy Effective for Breast Cancer?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
On July 21, 2022, Javier Cortes and colleagues from the International Breast Cancer Center (IBCC) published the results of the MK-3475-355/KEYNOTE-355 Phase III clinical trial on the efficacy and safety of the anti-PD-1 antibody Keytruda + chemotherapy in previously untreated advanced triple-negative breast cancer patients in the medical journal The New England Journal of Medicine.
The MK-3475-355/KEYNOTE-355 Phase III clinical trial randomized previously untreated patients with advanced triple-negative breast cancer (N = 847) in a 2:1 ratio into two groups: Keytruda (200mg) + chemotherapy group (21-day treatment cycles, N = 566) and placebo + chemotherapy group (N = 281). The primary efficacy endpoints were progression-free survival and overall survival in PD-L1-positive patients (CPS ≥10).
At the interim analysis with a median follow-up of 44.1 months, the results showed that in PD-L1-positive patients (CPS ≥10), the median overall survival was 23.0 months in the Keytruda + chemotherapy group versus 16.1 months in the placebo + chemotherapy group. In PD-L1-positive patients (CPS ≥1), the median overall survival was 17.6 months in the Keytruda + chemotherapy group versus 16.0 months in the placebo + chemotherapy group.
Additionally, regarding safety, the incidence of Grade 3-5 adverse events was 68.1% in the Keytruda + chemotherapy group versus 66.9% in the placebo + chemotherapy group.
Based on the results of the MK-3475-355/KEYNOTE-355 trial, Javier Cortes and colleagues concluded that previously untreated advanced triple-negative breast cancer patients (CPS ≥10) treated with the anti-PD-1 antibody Keytruda + chemotherapy showed improved overall survival compared to the placebo + chemotherapy group.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2202809?query=featured_home
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4